In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical trials.

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...

Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already ...

Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...

French drugmaker Sanofi has agreed to buy autoimmune disease therapy DR-0201 developed by Serbian-founded, US-based ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

Management expressed confidence in achieving further milestones in 2025, supported by partnerships with Roche and Sanofi. CEO Gibson noted that the partnership milestones generated $45 million in ...